Quarterly Activity Report & Appendix 4C - 31 December 2020
Filed with ASX · · 13 pages · English
FY21 (unaudited) to $4.5m SYDNEY Australia Wednesday, 27 January 2021 – Australian rapid blood test company quarterly activities report for the three-month period ended 31 December 2020 (Q2 FY21). Atomo’s cash position continues to be strong as customer receipts, and receipt of the Company’s R&D tax rebate supported ongoing investment in inventory, manufacturing COVID‐19rapidtestingdetectsSARS‐COV
Story so far
Earlier from Atomo Diagnostics
- Atomo provides update on its HIV Rapid Test business
- Atomo receives TGA approval for AtomoRapid HIV (1&2) test
- Managing Directors AGM Presentation
- Quarterly Activity Report & Appendix 4C - 30 September 2020
- Atomo receives TGA approval for COVID19 antigen test
Later from Atomo Diagnostics
- S&P DJI Announces March 2021 Quarterly Rebalance
- Viatris & Atomo to Support Unitaid HIV Self-Test Expansion
- Quarterly Activity Report & Appendix 4C - 31 March 2021
- Update to Atomos US market strategy
- Access Bio receives FDA clearance for COVID-19 antibody test
Follow Atomo Diagnostics into a list and get an email when it puts out news.
Follow Atomo Diagnostics